Suppr超能文献

其特异性抑制剂PAI-2对癌细胞尿激酶型纤溶酶原激活剂的抑制作用及对细胞外基质降解的后续影响。

Inhibition of cancer cell urokinase plasminogen activator by its specific inhibitor PAI-2 and subsequent effects on extracellular matrix degradation.

作者信息

Baker M S, Bleakley P, Woodrow G C, Doe W F

机构信息

Division of Clinical Sciences, John Curtin School of Medical Research, Australian National University, Canberra.

出版信息

Cancer Res. 1990 Aug 1;50(15):4676-84.

PMID:2114945
Abstract

Isotopically labeled [( 3H]serine, [3H]proline, and [35S]sulfate) subendothelial cell basement membranes were used to determine the role of urokinase plasminogen activator (uPA) and its specific inhibitor plasminogen activator inhibitor 2 (PAI-2) in colon cancer cell extracellular matrix degradation. Recombinant PAI-2 irreversibly inhibited low and high molecular weight purified human uPA in addition to both colon cancer cell-associated and secreted uPA, particularly if pro-uPA had been preactivated. Two selected lines (COLO394 and LIM1215) preferentially degraded differently labeled matrices in a time- and plasminogen-dependent manner. This process was inhibitable by PAI-2 in the medium at levels which suggested that some degree of "shielding" of cell surface uPA from inhibitor occurred. The ability of PAI-2 to regulate the invasive phenotype of cells which express cell surface or receptor-bound uPA is discussed.

摘要

利用同位素标记的([³H]丝氨酸、[³H]脯氨酸和[³⁵S]硫酸盐)内皮下细胞基底膜来确定尿激酶型纤溶酶原激活剂(uPA)及其特异性抑制剂纤溶酶原激活剂抑制剂2(PAI-2)在结肠癌细胞外基质降解中的作用。重组PAI-2除了能不可逆地抑制与结肠癌细胞相关的和分泌的uPA(特别是在pro-uPA已被预激活的情况下)外,还能抑制低分子量和高分子量的纯化人uPA。两个选定的细胞系(COLO394和LIM1215)以时间和纤溶酶原依赖性方式优先降解不同标记的基质。该过程可被培养基中的PAI-2抑制,其水平表明细胞表面uPA存在一定程度的免受抑制剂“屏蔽”。本文讨论了PAI-2调节表达细胞表面或受体结合型uPA的细胞侵袭表型的能力。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验